Treatment of leprosy

Clinics in Dermatology

Volumn 33, Issue 1, 2015, Pages 55-65

  Kar, Hemanta Kumar ^a   Gupta, Ruchi ^a  

^a DR RAM MANOHAR LOHIA HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BCG VACCINE; CLARITHROMYCIN; CLOFAZIMINE; DAPSONE; DRUG ADMINISTRATION; LEPROSTATIC AGENT; LEPROSY VACCINE; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; RIFAPENTINE; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; DIAGNOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG COMBINATION; DRUG EFFECTS; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG THERAPY; FEMALE; HUMAN; IMMUNOTHERAPY; LEPROSY; MALE; MONOTHERAPY; MYCOBACTERIUM LEPRAE; NOTE; PLASTIC SURGERY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; VACCINATION; WORLD HEALTH ORGANIZATION;

ADMINISTRATION AND DOSAGE; ANTI-BACTERIAL AGENTS; CLOFAZIMINE; DAPSONE; DIAGNOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EFFECTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; PROGNOSIS; RIFAMPIN; RISK ASSESSMENT; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 84963975622     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2014.07.007     Document Type: Note

References (45)

1. World Health Organization Media centre: leprosy fact sheet Available at. http://www.who.int/mediacentre/factsheets/fs101/en/index.html.
2. Gautam V.P. Treatment of leprosy in India. J Postgrad Med 2009, 55:220-224.
3. Faget G.H. Chemotherapy of leprosy. Int J Lepr 1947, 15:7-14.
4. Desai A.C., Bhide M.B. Hydnocarpus oil as an anti-leprotic agent in mouse foot-pad technique. Lepr India 1977, 49:360-363.
5. Colman M.D. Dapsone: mode of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993, 129:507-513.
6. Campbell E.A., Korzheva N., Mustaev A., et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001, 104:901-912.
7. Morrison M.E., Morley G.E. Clofazimine binding with deoxyribonucleic acid. Int J Lepr 1976, 44:475-481.
8. Anderson R. Enhancement by Clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leucocytes in vitro. Antimicrob Agents Chemother 1985, 27:257-262.
9. Ren Y.R., Pan F., Parvez S., Fleig A., Chong C.R. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One 2008, 3(12):e4009-e4020.
10. Kar H.K., Bhatia V.N., Harikrishnan S. Combined clofazimine and dapsone-resistant leprosy, a case report. Int J Lepr 1986, 54:389-391.
11. World Health Organization Multidrug therapy of leprosy Available at. http://www.who.int/lep/mdt/en/.
12. Ganapati R., Pai V.V., Rao R. Development and evolution of WHO MDT and newer treatment regimens. IAL Textbook of Leprosy 2010, 353-367. Jaypee Brothers Medical Publishers, New Delhi. H.K. Kar, K. Bhushan (Eds.).
13. Gupta R., Kar H.K., Bhardwaj M. Revalidation of various clinical criteria for the classification of leprosy-a clinic-pathological study. Lepr Rev 2012, 83:354-362.
14. Prasad P.V., Babu A., Kaviarasan P.K., Viswanathan P., Tippoo R. MDT-MB therapy in paucibacillary leprosy: a clinicopathological assessment. Indian J Dermatol Venereol Leprol 2005, 71:242-245.
15. Singh H., Nel B., Dey V., Tiwari P., Dulhani N. Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh state (Bastar, Jagdalpur). Lepr Rev 2011, 82:17-24.
16. World Health Organization Enhanced global strategy for further reducing the disease burden due to leprosy (2011-2015), operational guideline (updated) Available at. http://www.searo.who.int/LinkFiles/GLP_GLP_2009-4.pdf.
17. Malathi M., Thappa D.M. Fixed-duration therapy in leprosy: limitations and opportunities. Indian J Dermatol 2013, 58:93-100.
18. Girdhar B.K., Girdhar A. Short course treatment of leprosy: present status Available at. http://icmr.nic.in/bufeb02.pdf.
19. Leprosy-new drug regimens Available at. http://www.who.int/tdr/research/progress/9900/methods%5Ftreatment/en/index5.html.
20. Ji B., Grosset J. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev 2000, 71:S81-S87.
21. Pattyn S., Grillone S. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. Lepr Rev 2002, 73:245-247.
22. Katoch K., Katoch V.M., Natrajan M., Sharma V.D., Singh H.B., Gupta U.D. Chemotherapy trials in MB leprosy using conventional and newer drugs pefloxacin and minocycline. Indian J Dermatol Venereol Leprol 2000, 66:18-25.
23. Tejasvi T., Khaitan B.K., Khanna N., Pandhi R.K., Singh M.K. Evaluation of a new fixed duration (12 weeks) multi-drug regimen of bactericidal drugs in multibacillary leprosy. Indian J Lepr 2006, 78:329-337.
24. World Health Organization Report of the Ninth Meeting of the WHO Technical Advisory Group on Leprosy Control 2008, WHO Regional Office for South-East Asia, New Delhi.
25. Kroger A., Pannikar V., Htoon M.T., Jamesh A., Katoch K., Krishnamurthy P. International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results. Trop Med Int Health 2008, 13:594-602.
26. Rao P.N., Suneetha S., Pratap D.V.S. Comparative study of uniform MDT in pauci and multibacillary leprosy patients over 24 months of observation. Lepr Rev 2009, 80:143-155.
27. WHO regional strategy for sustaining leprosy services and further reducing the burden of leprosy 2006-2010. Indian J Lepr 2006, 78:33-47.
28. Sharma P., Kar H.K., Misra R.S. Reactional states and neuritis in multibacillary leprosy patients following MDT with/without immunotherapy with Mw anti-leprosy vaccine. Lepr Rev 2000, 71:193-205.
29. Rawat K.D., Chahar M., Reddy P.V., et al. Expression of CXCL10 (IP-10) and CXCL11 (I-TAC) chemokines during Mycobacterium tuberculosis infection and immunoprophylaxis with Mycobacterium indicus pranii (Mw) in guinea pig. Infect Genet Evol 2013, 13:11-17.
30. Merle C.S., Cunha S.S., Rodrigues L.C. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 2010, 9:209-222.
31. Gupta A., Geetha N., Mani J., Upadhyay P., Katoch V.M., Natrajan M. Immunogenicity and protective efficacy of "Mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route. Infect Immun 2009, 77:223-231.
32. Cunha S.S., Alexander N., Barreto M.L., Pereira E.S., Dourado I., de Maroja M. F. BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial. PLoS Negl Trop Dis 2008, 2(2):e167-e175.
33. Lockwood D.N., Cunha M.G. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally. Lepr Rev 2012, 83:241-244.
34. Setia M.S., Shinde S.S., Jerajani H.R., Boivin J.F. Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis: ROM therapy in leprosy: a systematic review and meta-analysis. Trop Med Int Health 2011, 16:1541-1551.
35. Villahermosa L.G., Fajardo T.T., Abalos R.M., et al. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. Am J Trop Med Hyg 2004, 70:197-200.
36. da Cunha M.G., Virmond M., Schettini A.P., et al. Ofloxacin multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil. Lepr Rev 2012, 83:261-268.
37. Girdhar A., Kumar A., Girdhar B.K. A randomised controlled trial assessing the effect of adding clarithromycin to rifampicin, ofloxacin and minocycline in the treatment of single lesion paucibacillary leprosy in Agra District, India. Lepr Rev 2011, 82:46-54.
38. Burgos J., de la Cruz E., Paredes R., Andaya C.R., Gelber R.H. The activity of several newer antimicrobials against logarithmically multiplying M. leprae in mice. Lepr Rev 2011, 82:253-258.
39. Liu P.T., Wheelwright M., Teles R., et al. MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat Med 2012, 18:267-273.
40. Shen J., Bathyala N., Kroeger A., et al. Bacteriological results and leprosy reactions among MB leprosy patients treated with uniform multidrug therapy in China. Lepr Rev 2012, 83:164-171.
41. Penna M.L., Buhrer-Sékula S., Pontes M.A., Cruz R., de Gonçalves H.S. Penna GO. Primary results of clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): reactions frequency in multibacillary patients. Lepr Rev 2012, 83:308-319.
42. de Gonçalves H.S., Pontes M.A., Bührer-Sékula S., Cruz R., Almeida P.C., de Moraes M.E. Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects. Mem Inst Oswaldo Cruz 2012, 107:S74-S78.
43. Maghanoy A., Mallari I., Balagon M., Saunderson P. Relapse study in smear positive multibacillary (MB) leprosy after 1 year WHO-multi-drug therapy (MDT) in Cebu Philippines. Lepr Rev 2011, 82:65-69.
44. Geluk A., van den Eeden S.J., Dijkman K., et al. ML1419c peptide immunization induces Mycobacterium leprae-specific HLA-A * 0201-restricted CTL in vivo with potential to kill live mycobacteria. J Immunol 2011, 187:1393-1402.
45. Raman V.S., O'Donnell J., Bailor H.R., et al. Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infect Immun 2009, 77:5623-5630.